Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

[Prostatic cancer in Sweden 1998-2003. Drastic change of the disease panorama].

Varenhorst E, Garmo H, Holmberg L, Stattin P, Johansson JE.

Lakartidningen. 2006 Feb 1-7;103(5):285-8. Swedish. No abstract available.

PMID:
16512566
2.

The evolving role of familial history for prostate cancer.

Colloca G, Venturino A.

Acta Oncol. 2011 Jan;50(1):14-24. doi: 10.3109/0284186X.2010.521191. Epub 2010 Sep 27. Review.

PMID:
20874046
3.

Mass screening for prostate cancer. The Swedish Council on Technology Assessment in Health Care.

[No authors listed]

Int J Cancer Suppl. 1996;9:1-72. No abstract available.

PMID:
8982323
4.

Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries.

Kvåle R, Auvinen A, Adami HO, Klint A, Hernes E, Møller B, Pukkala E, Storm HH, Tryggvadottir L, Tretli S, Wahlqvist R, Weiderpass E, Bray F.

J Natl Cancer Inst. 2007 Dec 19;99(24):1881-7. Epub 2007 Dec 11.

PMID:
18073376
5.

Prostate cancer--the snowball is rolling.

Ruutu M, Salo J, Nordling S, Rannikko S.

Ann Chir Gynaecol. 1999;88(1):5-8. Review. No abstract available.

PMID:
10230675
6.

The natural history of clinical prostate carcinoma.

Abbas F, Scardino PT.

Cancer. 1997 Sep 1;80(5):827-33. Review. No abstract available.

PMID:
9307180
7.
8.

[The National Board of Health and Welfare's guidelines for prostatic cancer care. PSA test screening--only for well-informed men].

Bratt O, Damber JE, Kärvinge C, Malm T, Hensjö LO, Hyttsten E.

Lakartidningen. 2008 Feb 20-26;105(8):524-8. Swedish. No abstract available.

PMID:
18363292
9.

Prostate cancer and prostate-specific antigen: facts, figures and commentary.

Chambers DC.

J Insur Med. 1993 Fall;25(3):336-40. No abstract available.

PMID:
10146433
10.

Prostate-specific antigen, risk factors, and prostate cancer: confounders nestled in an enigma.

Thompson IM, Ankerst DP, Tangen CM.

J Natl Cancer Inst. 2010 Sep 8;102(17):1299-301. doi: 10.1093/jnci/djq313. Epub 2010 Aug 19. No abstract available.

11.

Re: Chromogranin A concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer.

Yashi M, Tokue A.

J Urol. 2003 Jun;169(6):2305; author reply 2305. No abstract available.

PMID:
12771784
12.

Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.

Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andrén O, Bill-Axelson A, Bratt O, Damber JE, Hellström K, Hellström M, Holmberg E, Holmberg L, Hugosson J, Johansson JE, Petterson B, Törnblom M, Widmark A, Stattin P.

Scand J Urol Nephrol. 2007;41(6):456-77.

PMID:
17934985
13.

Prostate cancer--what should be studied?

James ND, Glaholm J.

Eur J Cancer. 1995 Sep;31A(10):1565-6. Review. No abstract available.

PMID:
7488401
14.

Current status of prostate cancer management in the prostate-specific antigen era.

Sartor O.

Clin Prostate Cancer. 2004 Mar;2(4):200-1. No abstract available.

PMID:
15072599
15.

[Prostate cancer].

Huland H, Wirth M.

Urologe A. 2000 Jan;39(1):2. German. No abstract available.

PMID:
10663188
16.

Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.

Ulmert D, Serio AM, O'Brien MF, Becker C, Eastham JA, Scardino PT, Björk T, Berglund G, Vickers AJ, Lilja H.

J Clin Oncol. 2008 Feb 20;26(6):835-41. doi: 10.1200/JCO.2007.13.1490.

PMID:
18281654
17.

Serologic markers in prostate cancer.

Harris D, Ruckle HC.

West J Med. 1996 Apr;164(4):344-5. No abstract available.

18.

Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials.

Collette L.

Eur Urol. 2008 Jan;53(1):6-9. Epub 2007 Aug 28. No abstract available.

PMID:
17764823
19.

Screening for prostate cancer in 2007: the PSA era and its challenges are not over.

Shariat SF, Karakiewicz PI.

Eur Urol. 2008 Mar;53(3):457-60. Epub 2007 Dec 7. No abstract available.

PMID:
18079050
20.

Prostate-specific antigen (PSA) and PSA velocity: competitors or collaborators in the prediction of curable and clinically significant prostate cancer.

D'Amico AV.

J Clin Oncol. 2008 Feb 20;26(6):823-4. doi: 10.1200/JCO.2007.15.1902. No abstract available.

PMID:
18281649

Supplemental Content

Support Center